ID   HCT116-SN50
AC   CVCL_Y553
DR   cancercelllines; CVCL_Y553
DR   Wikidata; Q54882059
RX   PubMed=15027118;
RX   PubMed=18340113;
RX   PubMed=21619602;
CC   Population: Caucasian.
CC   Doubling time: 23.2 hours (PubMed=21619602).
CC   Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Leu617Ile (c.1849C>A); Zygosity=Homozygous (PubMed=21619602).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B7PT ! HCT116-s
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=15027118; DOI=10.1002/ijc.20032;
RA   Candeil L., Gourdier I., Peyron D., Vezzio-Vie N., Copois V., Bibeau F.,
RA   Orsetti B., Scheffer G.L., Ychou M., Khan Q.A., Pommier Y., Pau B.,
RA   Martineau P., Del Rio M.;
RT   "ABCG2 overexpression in colon cancer cells resistant to SN38 and in
RT   irinotecan-treated metastases.";
RL   Int. J. Cancer 109:848-854(2004).
//
RX   PubMed=18340113; DOI=10.4161/cbt.7.6.5838;
RA   Gongora C., Candeil L., Vezzio-Vie N., Copois V., Denis V., Bareil C.,
RA   Molina F., Fraslon C., Conseiller E., Pau B., Martineau P.,
RA   Del Rio M.;
RT   "Altered expression of cell proliferation-related and
RT   interferon-stimulated genes in colon cancer cells resistant to SN38.";
RL   Cancer Biol. Ther. 7:822-832(2008).
//
RX   PubMed=21619602; DOI=10.1186/1476-4598-10-64;
RA   Gongora C., Vezzio-Vie N., Tuduri S., Denis V., Causse A.,
RA   Auzanneau C., Collod-Beroud G., Coquelle A., Pasero P., Pourquier P.,
RA   Martineau P., Del Rio M.;
RT   "New topoisomerase I mutations are associated with resistance to
RT   camptothecin.";
RL   Mol. Cancer 10:64.1-64.13(2011).
//